XTX Topco Ltd purchased a new position in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 43,740 shares of the company's stock, valued at approximately $237,000. XTX Topco Ltd owned approximately 0.06% of Eyepoint Pharmaceuticals as of its most recent SEC filing.
Other large investors have also modified their holdings of the company. Summit Investment Advisors Inc. boosted its holdings in shares of Eyepoint Pharmaceuticals by 39.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company's stock valued at $51,000 after buying an additional 1,940 shares in the last quarter. GAMMA Investing LLC raised its position in Eyepoint Pharmaceuticals by 3,174.4% in the 1st quarter. GAMMA Investing LLC now owns 10,249 shares of the company's stock valued at $56,000 after purchasing an additional 9,936 shares during the last quarter. Virtus ETF Advisers LLC purchased a new stake in Eyepoint Pharmaceuticals in the 4th quarter valued at $67,000. Raymond James Financial Inc. purchased a new stake in Eyepoint Pharmaceuticals in the 4th quarter valued at $76,000. Finally, Arizona State Retirement System raised its position in Eyepoint Pharmaceuticals by 12.7% in the 1st quarter. Arizona State Retirement System now owns 16,600 shares of the company's stock valued at $90,000 after purchasing an additional 1,877 shares during the last quarter. Institutional investors and hedge funds own 99.41% of the company's stock.
Eyepoint Pharmaceuticals Trading Up 2.2%
Shares of EYPT traded up $0.24 during trading hours on Friday, reaching $11.09. The company had a trading volume of 801,214 shares, compared to its average volume of 639,578. The firm has a 50 day simple moving average of $9.91 and a 200-day simple moving average of $7.55. The company has a market capitalization of $764.43 million, a price-to-earnings ratio of -4.14 and a beta of 1.73. Eyepoint Pharmaceuticals, Inc. has a 12-month low of $3.91 and a 12-month high of $13.98.
Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.18). The company had revenue of $5.33 million during the quarter, compared to analysts' expectations of $6.82 million. Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative return on equity of 63.80%. Sell-side analysts forecast that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several analysts recently commented on the stock. HC Wainwright upped their price target on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the company a "buy" rating in a research report on Wednesday, August 6th. Chardan Capital reiterated a "buy" rating and issued a $27.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Thursday, August 7th. Royal Bank Of Canada began coverage on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, June 17th. They set an "outperform" rating and a $28.00 price objective for the company. Finally, Mizuho cut their price objective on shares of Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a research report on Friday, May 16th. One equities research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $25.38.
Check Out Our Latest Analysis on EYPT
Eyepoint Pharmaceuticals Company Profile
(
Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Featured Stories
Before you consider Eyepoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eyepoint Pharmaceuticals wasn't on the list.
While Eyepoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access